MiniMed Group, Inc. logo

MiniMed Group, Inc. (MMED)

Market Open
11 Sep, 15:13
NASDAQ (NMS) NASDAQ (NMS)
$
22. 49
+0.05
+0.2228%
$
6.55B Market Cap
- P/E Ratio
- Div Yield
285,441 Volume
- Eps
$ 22.44
Previous Close
Investors:
Add Transaction
Day Range
22.48 23.74
Year Range
10.65 24.43
Want to track MMED and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MMED trading today higher at $22.49, an increase of 0.2228% from yesterday's close, completing a monthly increase of 21.6991% or $4.01. Over the past 12 months, MMED stock gained 18.0577%.
MMED is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

MMED Chart

People also search for

Lantheus Holdings, Inc.
$ 100.44
+0.0516%
Ollie's Bargain Outlet Holdings Inc.
$ 72.27
+0.4929%
Hovnanian Enterprises, Inc. Preferred Stock 7.625% Perpetual
$ 20.14
+4.2978%
Alvotech S.A.
$ 0.3
-1.5%
Supernus Pharmaceuticals Inc.
$ 41.84
+0.3718%
MiniMed Group: Recurring Revenues And Fresh Product Cycle

MiniMed Group: Recurring Revenues And Fresh Product Cycle

MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.

Seekingalpha | 1 week ago
MiniMed Group Q1 Earnings Call Highlights

MiniMed Group Q1 Earnings Call Highlights

MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.

Marketbeat | 1 week ago
MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating

MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating

MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements.

Seekingalpha | 1 month ago

MiniMed Group, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Chilton Investment
Chilton Investment Chilton Investment Co Inc.
232,299 $3.47M $5.29M $1.82M 52.45%
Point72 Asset Management LP
Point72 Asset Management LP Point72 Asset Management LP
15,395 $229,693.41 $310,055.3 $80,361.89 34.99%
Joseph Castro
Joseph Castro Nuveen LLC
539,313 $8.06M $12.31M $4.25M 52.71%
Regan O'Neill
Regan O'Neill Burkehill Global Management LP
300,000 $4.48M $6.99M $2.51M 56.07%
Hui Fai Tam
Hui Fai Tam Caitong International Asset Management Co. Ltd.
3,282 $49,066 $74,698.32 $25,632.32 52.24%

MiniMed Group, Inc. (MMED) FAQ

What is the stock price today?

The current price is $22.49.

On which exchange is it traded?

MiniMed Group, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is MMED.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 6.55B.

Has MiniMed Group, Inc. ever had a stock split?

No, there has never been a stock split.

MiniMed Group, Inc. Profile

Diversified Consumer Services Industry
Consumer Discretionary Sector
Que Thanh Dallara CEO
NASDAQ (NMS) Exchange
60365F109 CUSIP
US Country
8,000 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

MiniMed Group, Inc. specializes in the development, manufacturing, and marketing of innovative medical devices designed specifically for diabetes management. Established in 1983 by Alfred E. Mann, the company is headquartered in Northridge, California. MiniMed Group focuses on creating solutions that empower individuals with diabetes and their healthcare providers to effectively monitor and regulate blood glucose levels, significantly improving patient outcomes and quality of life.

Products and Services

  • Insulin Pumps: MiniMed's insulin pumps are designed to deliver precise doses of insulin to manage blood sugar levels continuously. These pumps offer features such as programmable dosages, bolus calculators, and customizable alerts, enabling users to maintain optimal glucose control throughout the day.
  • Continuous Glucose Monitoring Systems: The continuous glucose monitoring (CGM) systems provided by MiniMed allow users to track their glucose levels in real-time. These devices use sensors placed under the skin to provide continuous readings and alerts for high or low blood sugar levels, enhancing the ability to manage diabetes proactively.
  • Infusion Sets: The infusion sets are essential components of the insulin delivery systems, designed to ensure the effective and comfortable administration of insulin. MiniMed's infusion sets come in various styles and sizes to accommodate individual patient needs, making it easier for users to maintain their therapy.
  • Software Platforms: MiniMed offers software platforms that integrate data from insulin pumps and CGM systems to provide comprehensive insights into a patient's glucose patterns. This information assists healthcare providers and patients in making informed decisions to optimize diabetes management strategies.
  • Related Accessories: Alongside its core products, MiniMed also supplies a range of accessories that support the functionality of its medical devices. This includes carrying cases, charging stations, and additional supplies necessary for the effective use of insulin pumps and monitoring systems.

Contact Information

Address: 18000 Devonshire Street
Phone: (763) 514-4000